Neurological Surgery 脳神経外科44巻9号

2016年09月発行

連載 脳腫瘍Update

（10）Pituitary adenoma（下垂体腺腫）

著者： 廣畑倫生¹² 石井雄道¹² 大山健一¹² 松野彰¹²

所属機関： ¹帝京大学医学部脳神経外科 ²帝京大学医学部下垂体・内視鏡手術センター

ページ範囲：P.793 - P.802

Ⅰ．はじめに
　トルコ鞍および傍鞍部に生じる腫瘍は頭蓋内腫瘍の10〜15%程度とされている．その多くは下垂体腺腫，頭蓋咽頭腫，髄膜腫などの良性腫瘍であり，その他にはラトケ囊胞，胚細胞腫瘍などが鞍内・傍鞍部腫瘤の大半を占める．非腫瘍性病変としては，ランゲルハンス細胞組織球症（Langerhans cell histiocytosis），リンパ球性下垂体炎，サルコイドーシスなどが鑑別診断として挙げられる．本稿では鞍内・傍鞍部腫瘍の代表である下垂体腺腫について，最近の研究を中心に述べていきたい．読者にとっては周知の内容と思われる一般的な下垂体腺腫の分類や診断基準，治療などについては割愛する．

参考文献

1) Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Panagiotou A, Kita M：Pituitary incidentalomas：a single-centre experience. Int J Clin Pract 65：172-177, 2011

2) Arita K, Tominaga A, Sugiyama K, Eguchi K, Iida K, Sumida M, Migita K, Kurisu K：Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg 104：884-891, 2006

3) Asa SL, Ezzat S：Genetics and proteomics of pituitary tumors. Endocrine 28：43-47, 2005

4) Aylwin SJ, Welch JP, Davey CL, Geddes JF, Wood DF, Besser GM, Grossman AB, Monson JP, Burrin JM：The relationship between steroidogenic factor 1 and DAX-1 expression and in vitro gonadotropin secretion in human pituitary adenomas. J Clin Endocrinol Metab 86：2476-2483, 2001

5) Balik V, Srovnal J, Sulla I, Kalita O, Foltanova T, Vaverka M, Hrabalek L, Hajduch M：MEG3：a novel long noncoding potentially tumour-suppressing RNA in meningiomas. J Neurooncol 112：1-8, 2013

6) Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN：Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82：818-824, 1997

7) Bhansali A, Sharma BS, Sreenivasulu P, Singh P, Vashisth RK, Dash RJ：Acromegaly with fibrous dysplasia：McCune-Albright Syndrome--clinical studies in 3 cases and brief review of literature. Endocr J 50：793-799, 2003

8) Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ；German Pegvisomant Observational Study：The German ACROSTUDY：past and present. Eur J Endocrinol 161 Suppl 1：S3-S10, 2009

9) Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S；“Italian Acrostudy Group”：Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J Endocrinol Invest 38：1099-1109, 2015

10) Chanson P, Brue T, Delemer B, Caron P, Borson-Chazot F, Zouater H；Médecins de l'Étude ACROSTUDY：Pegvisomant treatment in patients with acromegaly in clinical practice：The French ACROSTUDY. Ann Endocrinol（Paris）76：664-670, 2015

11) Colao A, Auriemma RS, Pivonello R：The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19：210-221, 2016

12) Cuevas-Ramos D, Fleseriu M：Pasireotide：a novel treatment for patients with acromegaly. Drug Des Devel Ther 10：227-239, 2016

13) Cushman LJ, Watkins-Chow DE, Brinkmeier ML, Raetzman LT, Radak AL, Lloyd RV, Camper SA：Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility. Hum Mol Genet 10：1141-1153, 2001

14) D'Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J, Fusco A：Altered microRNA expression profile in human pituitary GH adenomas：down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab 97：E1128-E1138, 2012

15) Dasen JS, O'Connell SM, Flynn SE, Treier M, Gleiberman AS, Szeto DP, Hooshmand F, Aggarwal AK, Rosenfeld MG：Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell 97：587-598, 1999

16) Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA, Pereira AM：The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 156：217-224, 2007

17) Donovan LE, Corenblum B：The natural history of the pituitary incidentaloma. Arch Intern Med 155：181-183, 1995

18) Egashira N, Minematsu T, Miyai S, Takekoshi S, Camper SA, Osamura RY：Pituitary changes in Prop1 transgenic mice：hormone producing tumors and signet-ring type gonadotropes. Acta Histochem Cytochem 41：47-57, 2008

19) Farrell WE：Epigenetic mechanisms of tumorigenesis. Horm Metab Res 37：361-368, 2005

20) Feldkamp J, Santen R, Harms E, Aulich A, Mödder U, Scherbaum WA：Incidentally discovered pituitary lesions：high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol（Oxf）51：109-113, 1999

21) Fernández-Balsells MM, Murad MH, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG, Erwin PJ, Carey J, Montori VM：Natural history of nonfunctioning pituitary adenomas and incidentalomas：a systematic review and metaanalysis. J Clin Endocrinol Metab 96：905-912, 2011

22) Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML；Endocrine Society：Pituitary incidentaloma：an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96：894-904, 2011

23) Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A；Pasireotide C2402 Study Group：Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly（PAOLA）:a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2：875-884, 2014

24) Goudakos JK, Markou KD, Georgalas C：Endoscopic versus microscopic trans-sphenoidal pituitary surgery：a systematic review and meta-analysis. Clin Otolaryngol 36：212-220, 2011

25) Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A：DNA mismatch repair protein（MSH6）correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide：the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98：1130-1136, 2013

26) Igarashi T, Saeki N, Yamaura A：Long-term magnetic resonance imaging follow-up of asymptomatic sellar tumors.--their natural history and surgical indications. Neurol Med Chir（Tokyo）39：592-598；discussion 598-599, 1999

27) Ishii Y, Suzuki M, Takekoshi S, Egashira N, Yamazaki M, Miyai S, Sanno N, Teramoto A, Osamura RY：Immunonegative “null cell” adenomas and gonadotropin（Gn）subunit（SUs）immunopositive adenomas share frequent expression of multiple transcription factors. Endocr Pathol 17：35-43, 2006

28) Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF：Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol 159：517-523, 2008

29) Kaltsas GA, Grossman AB：Malignant pituitary tumours. Pituitary 1：69-81, 1998

30) Kaltsas GA, Kola B, Borboli N, Morris DG, Gueorguiev M, Swords FM, Czirják S, Kirschner LS, Stratakis CA, Korbonits M, Grossman AB：Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin Endocrinol（Oxf）57：443-448, 2002

31) Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA：What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol（Oxf）67：938-943, 2007

32) Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL：Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74：914-919, 1992

33) Kim EH, Ku CR, Lee EJ, Kim SH：Extracapsular en bloc resection in pituitary adenoma surgery. Pituitary 18：397-404, 2015

34) Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA：Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26：89-92, 2000

35) Kobayashi I, Oka H, Naritaka H, Sato Y, Fujii K, Kameya T：Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas：difference among functioning, silent, and other nonfunctioning adenomas. Endocr Pathol 13：83-98, 2002

36) Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J：A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 104：849-859, 2001

37) Lee CC, Vance ML, Xu Z, Yen CP, Schlesinger D, Dodson B, Sheehan J：Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99：1273-1281, 2014

38) Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Truillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E, DeLellis RA, Heitz PU：Pituitary tumors：Introduction. In DeLellis RA, Lloyd RV, Heitz PU, Eng C（eds）:WHO classification of tumours, vol.8：Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, 2004, pp10-13

39) Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escolá C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castaño JP, Bernabeu I：Somatotroph tumor progression during pegvisomant therapy：a clinical and molecular study. J Clin Endocrinol Metab 96：E251-E259, 2011

40) Melmed S：Mechanisms for pituitary tumorigenesis：the plastic pituitary. J Clin Invest 112：1603-1618, 2003

41) Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY：PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 17：143-153, 2006

42) Miyai S, Yoshimura S, Iwasaki Y, Takekoshi S, Lloyd RV, Osamura RY：Induction of GH, PRL, and TSH beta mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line. Cell Tissue Res 322：269-277, 2005

43) Mizokami Y, Egashira N, Takekoshi S, Itoh J, Itoh Y, Osamura RY, Matsumae M：Expression of MSX1 in human normal pituitaries and pituitary adenomas. Endocr Pathol 19：54-61, 2008

44) Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH：Use of the histological pseudocapsule in surgery for Cushing disease：rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116：721-727, 2012

45) Morita K, Takano K, Yasufuku-Takano J, Yamada S, Teramoto A, Takei M, Osamura RY, Sano T, Fujita T：Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4（ptd-FGFR4）correlates with tumour invasiveness but not with G-protein alpha subunit（gsp）mutation in human GH-secreting pituitary adenomas. Clin Endocrinol（Oxf）68：435-441, 2008

46) Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jørgensen JO, van der Lely AJ：Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99：3644-3652, 2014

47) Nishizawa S, Ohta S, Yokoyama T, Uemura K：Therapeutic strategy for incidentally found pituitary tumors（“pituitary incidentalomas”). Neurosurgery 43：1344-1348；discussion 1348-1350, 1998

48) Oyama K, Sanno N, Teramoto A, Osamura RY：Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol 14：892-899, 2001

49) Pei L, Melmed S：Isolation and characterization of a pituitary tumor-transforming gene（PTTG). Mol Endocrinol 11：433-441, 1997

50) Poulin G, Turgeon B, Drouin J：NeuroD1/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 17：6673-6682, 1997

51) Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL：Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85：464-473, 2005

52) Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S：Pathohistological classification of pituitary tumors：10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156：203-216, 2007

53) Sanno N, Teramoto A, Matsuno A, Takekoshi S, Itoh J, Osamura RY：Expression of Pit-1 and estrogen receptor messenger RNA in prolactin-producing pituitary adenomas. Mod Pathol 9：526-533, 1996

54) Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y：A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 149：123-127, 2003

55) Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV：Pituitary carcinoma：a clinicopathological review. Neurosurgery 56：1066-1074, 2005

56) Shimatsu A, Nagashima M, Hashigaki S, Ohki N, Chihara K：Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly. Endocr J 63：337-347, 2016

57) Shupnik MA, Weinmann CM, Notides AC, Chin WW：An upstream region of the rat luteinizing hormone beta gene binds estrogen receptor and confers estrogen responsiveness. J Biol Chem 264：80-86, 1989

58) Spada A, Lania A, Ballarè E：G protein abnormalities in pituitary adenomas. Mol Cell Endocrinol 142：1-14, 1998

59) Stewart PM：Pegvisomant：an advance in clinical efficacy in acromegaly. Eur J Endocrinol 148 Suppl 2：S27-32, 2003

60) Stilling G, Sun Z, Zhang S, Jin L, Righi A, Kovācs G, Korbonits M, Scheithauer BW, Kovacs K, Lloyd RV：MicroRNA expression in ACTH-producing pituitary tumors：up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine 38：67-75, 2010

61) Tahir A, Chahal HS, Korbonits M：Molecular genetics of the aip gene in familial pituitary tumorigenesis. Prog Brain Res 182：229-253, 2010

62) Thakker RV：Multiple endocrine neoplasia type 1（MEN1). Best Pract Res Clin Endocrinol Metab 24：355-370, 2010

63) Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montañana CF, Hana V, Halaby G, Delemer B, Aizpún JI, Sonnet E, Longás AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A：High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165：509-515, 2011

64) Umeoka K, Sanno N, Osamura RY, Teramoto A：Expression of GATA-2 in human pituitary adenomas. Mod Pathol 15：11-17, 2002

65) Vandeva S, Tichomirowa MA, Zacharieva S, Daly AF, Beckers A：Genetic factors in the development of pituitary adenomas. Endocr Dev 17：121-133, 2010

66) Vortmeyer AO, Gläsker S, Mehta GU, Abu-Asab MS, Smith JH, Zhuang Z, Collins MT, Oldfield EH：Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metab 97：2404-2413, 2012

67) Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M, Saito S, Itakura M：ras mutations in endocrine tumors：mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83：1057-1062, 1992

68) Zafar M, Ezzat S, Ramyar L, Pan N, Smyth HS, Asa SL：Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80：3621-3627, 1995

69) Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S：Pituitary tumor transforming gene（PTTG）expression in pituitary adenomas. J Clin Endocrinol Metab 84：761-767, 1999

70) Zhang X, Zhou Y, Klibanski A：Isolation and characterization of novel pituitary tumor related genes：a cDNA representational difference approach. Mol Cell Endocrinol 326：40-47, 2010

71) Zhou Y, Zhang X, Klibanski A：MEG3 noncoding RNA：a tumor suppressor. J Mol Endocrinol 48：R45-53, 2012